Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

5697 - Prognostic role of blood cell count-based immuno-inflammatory parameters in the Valentino trial


29 Sep 2019


Poster Display session 2


Tumour Site

Colon and Rectal Cancer


Giovanni Fuca


Annals of Oncology (2019) 30 (suppl_5): v198-v252. 10.1093/annonc/mdz246


G. Fuca1, V. Guarini1, S. Corallo1, S. Lonardi2, A. Raimondi1, G. Peverelli1, L. Rimassa3, C. Antoniotti4, R. Murialdo5, A. Zaniboni6, A. Sartore-Bianchi7, G. Tomasello8, P. Racca9, M. Clavarezza10, V. Adamo11, M. Prisciandaro1, F. Palermo1, M. Di Bartolomeo1, F.G.M. De Braud1, F. Pietrantonio1

Author affiliations

  • 1 Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, 20133 - Milan/IT
  • 2 Unit Of Medical Oncology 1, Department Of Clinical And Experimental Oncology, Veneto Institute Of Oncology, IOV - IRCSS, 35128 - Padova/IT
  • 3 Medical Oncology And Hematology Unit, Humanitas Cancer Center, 20089 - Rozzano/IT
  • 4 Translational Research Research And New Technologies In Medicine, Azienda Ospedaliero-Universitaria Pisana, 56126 - Pisa/IT
  • 5 Department Of Internal Medicine, IRCCS AOU San Martino-IST, 16132 - Genoa/IT
  • 6 Medical Oncology Unit, Poliambulanza Foundation, 25124 - Brescia/IT
  • 7 Niguarda Cancer Center And Department Of Oncology And Hemato-oncology, Grande Ospedale Metropolitano Niguarda and University of Milan, Milan/IT
  • 8 Oncology Unit, Oncology Department, ASST of Cremona, Cremona/IT
  • 9 Medical Oncology Unit, AOU Città della Salute e della Scienza, 10126 - Torino/IT
  • 10 Medical Oncology Unit, Ente ospedaliero Ospedali Galliera, 16128 - Genova/IT
  • 11 Medical Oncology Unit, A.O. Papardo, 98158 - Messina/IT


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 5697


We aimed to investigate the association between blood cell count-based immuno-inflammatory parameters, clinico-pathological characteristics and clinical outcomes in patients (pts) with RAS wt, metastatic colorectal cancer (mCRC) randomized to panitumumab (pani) plus FOLFOX4 induction followed by maintenance with pani +/- 5FU/LV in the phase 2 Valentino study.


Pts in the intention-to-treat population (n = 229) were screened for the availability of pre-treatment complete blood cell count. We focused on neutrophil-to-lymphocyte ratio (NLR), absolute monocyte count (AMC) and platelet count (PC). NLR and AMC were defined high if ≥ 4 and 900/mcl, respectively, based on literature data. PC was defined high if > of the median value of the study population. The Kaplan-Meier method and Cox proportional hazards regression model were used for survival analyses.


A total of 215 pts were included. NLR and AMC were significantly associated with ECOG PS. AMC and PC were associated with the presence of synchronous metastases and primary tumor resection. After a median follow-up of 26.7 months, high NLR was associated with worse progression-free survival [PFS] (HR 1.51, p = 0.015) and overall survival [OS] (HR 2.18, p < 0.001), as well as high AMC (HR for PFS 1.85, p = 0.003; HR for OS 2.49, p < 0.001) and high PC (HR for PFS 1.65, p = 0.001; HR for OS 1.85, p = 0.003). In the multivariable models, only PC confirmed its independent association with both clinical outcomes (HR for PFS 1.71, p < 0.001; HR for OS 1.70, p = 0.01), while AMC was only independently associated with PFS (HR 2.44, p = 0.03) and NLR did not demonstrate any significant association. The PFS benefit of adding 5-FU/LV to pani in the maintenance setting was independent from NLR and AMC (interaction p = 0.15 and p = 0.48, respectively), but was retained only in the subgroup with low PC (interaction p = 0.04). No significantly association with response or disease control was observed.


In pts with RAS wt, mCRC randomized in the Valentino study, baseline PC showed and independent association with OS and PFS and baseline AMC was independently associated with PFS. Pts with high PC did not derive any PFS benefit from the addiction of 5-FU/LV to pani in the maintenance setting.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

The authors.


Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Amgen.


S. Lonardi: Honoraria (self): Roche; Honoraria (self): Amgen; Honoraria (self): Bayer; Honoraria (self): Merck-Serono; Honoraria (self): Servier; Honoraria (self): Bristol-Myers Squibb. L. Rimassa: Honoraria (self): AstraZeneca; Honoraria (self): AbbVie; Honoraria (self): Lilly; Honoraria (self): Bayer; Honoraria (self): Sirtex Medical; Honoraria (self): Italfarmaco; Honoraria (self): Sanofi; Honoraria (self): ArQule; Honoraria (self): Baxter; Honoraria (self): Ipsen; Honoraria (self): Exelixis; Honoraria (self): Amgen; Honoraria (self): Incyte; Honoraria (self): Celgene. A. Zaniboni: Honoraria (self): Sanofi; Honoraria (self): Amgen; Honoraria (self): Bayer; Honoraria (self): Merck-Serono; Honoraria (self): Roche. A. Sartore-Bianchi: Honoraria (self): Sanofi; Honoraria (self): Amgen; Honoraria (self): Bayer; Honoraria (self): Merck-Serono; Honoraria (self): Roche. M. Di Bartolomeo: Honoraria (self): Amgen; Honoraria (self): Roche; Honoraria (self): Lilly; Honoraria (self): Servier; Honoraria (self): Incyte; Honoraria (self): Celgene. F.G.M. De Braud: Honoraria (self): Amgen; Honoraria (self): Roche; Honoraria (self): Novartis. F. Pietrantonio: Honoraria (self): Sanofi; Honoraria (self): Amgen; Honoraria (self): Bayer; Honoraria (self): Merck-Serono; Honoraria (self): Roche; Honoraria (self): Servier. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.